The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...

HER2-positive (HER2+) HER2-positive breast cancer is cancer that tests positive for a protein ... Triple-negative These tumors are ER-negative (ER-), PR-negative (PR-), and HER2-negative (HER2-). This ...

Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death.

The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...

This study assessed CDK4/6 inhibitor maintenance therapy in ER-positive, HER2-positive advanced breast cancer. Patients receiving palbociclib plus aromatase inhibitors after induction therapy ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

A phase 2 trial finds that for patients with HER2+ metastatic colorectal cancer, dual HER2-inhibitor therapy can be a similarly efficacious but less toxic alternative to EGFR inhibitor therapy.

The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

The 2024 San Antonio Breast Cancer Symposium showcased significant advancements in hormone receptor-positive, HER2-negative breast cancer research, including findings from the PADMA study ...